大肠杆菌ST131驱动大肠杆菌血流感染的碳青霉烯类使用
一项美国14个中心的前瞻性队列研究纳入282例大肠杆菌血流感染患者,比较ST131与非ST131菌株感染。结果显示79%的ST131对头孢曲松耐药,ST131感染者的总体和经验性碳青霉烯类使用率显著更高,但30天desirability of outcome ranking结局无差异。
要点
- ST131占大肠杆菌血流感染的43%,其中23%为C2/H30Rx亚克隆。
- ST131感染者总体碳青霉烯使用率74%,显著高于非ST131的31%。
- ST131感染者经验性碳青霉烯使用率48%,亦显著高于非ST131的19%。
核心结论
- 美国大肠杆菌血流感染中头孢曲松耐药菌株多属于ST131,尤其是C2/H30Rx亚克隆,是碳青霉烯类使用的重要驱动因素。
研究设计与样本
- 前瞻性队列研究,纳入美国14个中心,按1:1比例入组头孢曲松耐药和敏感的单微生物大肠杆菌血流感染病例。
- 共分析282例患者,其中ST131占43%(121/282),C2/H30Rx亚克隆占23%(66/282)。
主要发现
- ST131对头孢曲松耐药比例为79%(96/121),C2/H30Rx为86%(57/66),非ST131为27%(43/161)。
- 两组30天desirability of outcome ranking结局相似。
临床怎么用
- 临床遇到大肠杆菌血流感染时,应意识到ST131尤其是C2/H30Rx亚克隆可能与头孢曲松耐药及碳青霉烯使用相关。
- 对于来自长期护理机构的老年大肠杆菌血流感染患者,需考虑ST131感染可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. METHODS: A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset. RESULTS: This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups. CONCLUSIONS: Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.
引用
- Mackow NA, Shao W, Ge L, et al. Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections. Clin Infect Dis. 2026. PMID: 41795867. doi:10.1093/cid/ciag160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。